{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-067797","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.718549+00:00","generated_at":"2026-06-18T05:44:31.560531+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Kymera reports limited SVB exposure of $2.2M cash and $4.5M letter of credit","bullets":["As of March 10, 2023, Kymera holds $2.2M cash at Silicon Valley Bank (SVB) and $4.5M restricted cash letter of credit.","Total cash and equivalents reported at $560M as of Dec 31, 2022; SVB exposure represents <1% of cash.","Company does not anticipate any material impact on operations or liquidity from SVB closure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-067797","json":"https://secwatch.observer/filing/0001193125-23-067797.json","markdown":"https://secwatch.observer/filing/0001193125-23-067797.md","text":"https://secwatch.observer/filing/0001193125-23-067797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523067797/0001193125-23-067797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523067797/d459968d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:44:31.560531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}